(See insructions): The Intervention Core (Core D) will provide a range of services to Center investigators to link with our community partners and to train investigators and providers to implement a broad range of interventions for treatment of mental illness, HIV, and their comorbidities. Specifically, Core D will: (1) Provide expert consultation on the design of HIV intervention projects with consistent consideration of integration of both biomedical and behavioral science;2) Assemble a library of manuals and other materials to facilitate access to and dissemination of evidence-based interventions for the treatment of mental illnesses and HIV;(3) Provide training for interventionists in the use of state-of-the-science interventions;and (4) Provide linkages with community-based providers for effectiveness trials. Many projects that Core D will support will be completed using established and standard methods, and we have an explicit preference for using manualized treatments in "real worid" settings and comparative effectiveness research methods. In some cases, however, it will be necessary to either adapt existing methods or devise new ones in order to achieve the goals of a particular project or initiative. In general. Core D will utilize personnel effort that is supported by the Core for pilot projects and preparation of funding proposals, with the subsequent funded grants providing direct support of the resulting collaborative research effort. Core D is dedicated to building a portfolio over time that will combine comparative effectiveness research, translation and implementation science, and community-based participatory research (CBPR) methods. Building on the unique capacities available at Penn, the Intervention Core will collaborate with other centers and institutes such as the Leonard Davis Institute of Health Economics in the Wharton School and the Annenberg Public Policy Center to conduct cost-effectiveness and other policy relevant analysis in order to plan for targeted dissemination to influence public health policy regarding treatment of HIV among persons with psychiatric conditions. We will provide assistance in grant proposal preparation;and potential users of the Core will be alerted of the resources.
Persons with mental illness who are also HIV seropositive are difficult to treat and there is dearth of information about best practices for these individuals. Improving care for these individuals will improve treatment outcomes and quality of life, and has the potential for also reducing costs. Further, reducing the community viral load for the HIV+ mentally ill population will very likely reduce transmission ofthe virus.
|Dowshen, Nadia; Matone, Meredith; Luan, Xianqun et al. (2016) Behavioral and Health Outcomes for HIV+ Young Transgender Women (YTW) Linked To and Engaged in Medical Care. LGBT Health 3:162-7|
|Barrett, Jeffrey S; Spitsin, Sergei; Moorthy, Ganesh et al. (2016) Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med 14:148|
|Douglas, Steven D (2016) Substance P and sickle cell disease-a marker for pain and novel therapeutic approaches. Br J Haematol 175:187-188|
|Lyons, Anita; Bilker, Warren B; Hines, Janet et al. (2016) Effect of format on comprehension of adherence data in chronic disease: A cross-sectional study in HIV. Patient Educ Couns 99:154-9|
|McGuire, Jennifer L; Gill, Alexander J; Douglas, Steven D et al. (2016) The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth. J Neurovirol 22:823-830|
|Greeson, Jeffrey M; Gettes, David R; Spitsin, Sergei et al. (2016) The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells. Biol Psychiatry 80:33-9|
|McGuire, Jennifer L; Gill, Alexander J; Douglas, Steven D et al. (2015) Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol 21:439-48|
|Springer, Sandra A; Larney, Sarah; Alam-Mehrjerdi, Zahra et al. (2015) Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. J Acquir Immune Defic Syndr 69 Suppl 2:S155-61|
|Yehia, Baligh R; Stephens-Shield, Alisa J; Momplaisir, Florence et al. (2015) Health Outcomes of HIV-Infected People with Mental Illness. AIDS Behav 19:1491-500|
|McGuire, Jennifer L; Kempen, John H; Localio, Russell et al. (2015) Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth. Clin Vaccine Immunol 22:27-36|
Showing the most recent 10 out of 23 publications